News | August 08, 2025
Biocon Q1 FY26 PAT slips 95% to Rs. 31.4 Cr
Revenue from operations rose 14.8 per cent year-on-year to Rs. 3,942 crore
Revenue from operations rose 14.8 per cent year-on-year to Rs. 3,942 crore
The submission is supported by results from the Phase 3b APEX study
A global platform advancing pharmaceutical collaboration, innovation, and exports—powering healthcare and connecting markets worldwide
For patients with resectable early-stage gastric and gastroesophageal junction cancers
The new facility will be the company’s fourth spinning plant for hollow-fiber cellulose membrane filters
The savings will be fully reinvested to support new product launches and its pipeline across multiple therapeutic areas
GSK and Hengrui Pharma enter agreements to develop up to 12 innovative medicines across Respiratory, Immunology & Inflammation and Oncology
Reported EBITDA up by 19% year-on-year with reported EBITDA margin at 25%
Based on the CRL, the STARGLO data do not provide sufficient evidence to support the proposed second-line DLBCL indication in the US patient population
FDA requests Sarepta Therapeutics to suspend distribution of Elevidys and places clinical trials on hold for multiple gene therapy products following 3 deaths
Subscribe To Our Newsletter & Stay Updated
